Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

REVANCE THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNC

RVNC

NEW ORLEANS, Dec. 15, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have untilFebruary 8, 2022 to file lead plaintiff applications in a securities class action lawsuit against Revance Therapeutics, Inc. (NasdaqGM: RVNC), if they purchased the Company's shares between November 25, 2019 and October 11, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

Get Help

Revance investors should visit us at https://claimsfiler.com/cases/nasdaq-rvnc-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Revance and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On October 12, 2021, the Company disclosed that on July 2, 2021, the FDA had notified it of problems observed during its inspection of the Company's Northern California DAXI manufacturing facility, including that "[t]he current manufacturing process is not the process proposed for licensure" and that the "Quality Unit lacks the responsibility and authority for control, review, and approval for outsourced activities[.]"

On this news, shares of Revance fell $6.85 per share, or 25%, to close at $20.45 per share on October 12, 2021.

The case is Aramic LLC v. Revance Therapeutics, Inc., No. 21-cv-09585.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Cision View original content:https://www.prnewswire.com/news-releases/revance-therapeutics-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-revance-therapeutics-inc---rvnc-301446022.html

SOURCE ClaimsFiler



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today